Skystar Bio-Pharmaceutical Company (SKBI) 3.79

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Skystar Bio-Pharmaceutical Company (SKBI) 3.79 $SKBI

InsiderInsights.com Daily Round Up 4/20/15: AXDX, BXMT, OPK, AGCO
InsiderInsights - at Seeking Alpha - Wed Apr 22, 10:38AM CDT

STFC: 23.83 (-0.01), SKBI: 3.79 (-0.11), DOOR: 68.54 (-0.82), MMI: 37.17 (-0.02), AGCO: 48.16 (-0.16), DEI: 29.37 (+0.22), ABDC: 13.70 (-0.19), CSX: 36.26 (+0.91), HOV: 3.36 (-0.08), MOH: 63.02 (-0.71), MEMP: 16.95 (-0.16), SFS: 18.08 (-0.49), AXDX: 23.62 (+0.10), OPK: 14.60 (+0.17), BXMT: 31.24 (+0.04), FELP: 13.99 (-0.33), CRM: 67.71 (+0.33)

Skystar Bio-Pharmaceutical Company Announces Receipt of NASDAQ Non-Compliance Letter Due to Delay in Filing Form 10-K
Marketwired - Wed Apr 15, 4:00PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification from the Nasdaq Stock Market ("Nasdaq" informing the Company that since it had not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2014, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted under its current trading symbol.
SKBI: 3.79 (-0.11)

InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST

GD: 133.71 (+0.57), SKBI: 3.79 (-0.11), PTBI: 3.37 (+0.20), FMD: 6.56 (+0.01), GHC: 1,068.93 (+24.92), VRML: 1.80 (-0.02), ADBE: 75.50 (+0.88), OHAI: 5.59 (+0.03), KERX: 11.52 (-0.15), BH: 396.99 (-5.47), LII: 107.70 (+2.09), JAZZ: 186.13 (-0.41), NMBL: 24.61 (-0.13), REGN: 472.63 (+9.41), OAS: 16.47 (-0.36), XLRN: 33.67 (-0.02), SYK: 96.45 (+1.74), CRM: 67.71 (+0.33)

Update: Skystar Bio-Pharmaceutical Company Q3 Earnings - Key Developments
David Zanoni - at Seeking Alpha - Wed Nov 19, 2:00AM CST

SKBI: 3.79 (-0.11)

Skystar Bio-Pharmaceutical Company (SKBI) Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 17, 6:48PM CST

SKBI: 3.79 (-0.11)

Skystar Bio reports Q3 profit
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 4:20PM CST

SKBI: 3.79 (-0.11)

Skystar Bio-Pharmaceutical Reports Third Quarter Fiscal Year 2014 Financial Results
Marketwired - Fri Nov 14, 4:01PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company" , a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today reported unaudited third quarter fiscal year 2014 earnings, for the period ended September 30, 2014.
SKBI: 3.79 (-0.11)

Skystar Bio-Pharmaceutical to File Financial Results for Third Quarter of Fiscal 2014 on Friday, November 14
Marketwired - Fri Nov 14, 12:00PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company" , a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its financial results for the third quarter of fiscal 2014 on Friday, November 14, 2014 by close of the business day.
SKBI: 3.79 (-0.11)

Skystar Bio-Pharma Featured on Wide World of Stocks Television
Marketwired - Wed Nov 05, 1:33PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that the interview of Mr. Scott Cramer, Director, Corporate Development and U.S. Representative for Skystar, on Wide World of Stocks will broadcast today, Wednesday, November 5, 2014 into more than 50 million homes nationwide over BizTV, BizTV Radio, and You Tube America Networks.
SKBI: 3.79 (-0.11)

Market Maker Surveillance Report. BDR, HDY, LUNA, EFOI, SKBI, KUTV, Losing Stocks With Lowest Price Friction For Friday, September 12th 2014
M2 - Mon Sep 15, 2:54AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4813 companies with "abnormal" market making, 1557 companies with positive Friction Factors and 3492 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Friday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Blonder Tongue Laboratories Inc (NYSE:BDR), Hyperdynamics Corp (NYSE:HDY), Luna Innovations Inc (NASDAQ:LUNA), Energy Focus Inc (NASDAQ:EFOI), Skystar Bio Pharmaceutical Co (NASDAQ:SKBI), Ku6 Media Co Ltd (NASDAQ:KUTV). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
SKBI: 3.79 (-0.11), LUNA: 1.38 (+0.02), EFOI: 5.18 (+0.14), BDR: 0.80 (+0.05), KUTV: 0.92 (unch), HDY: 0.67 (-0.04)

3 Stocks Under $10 Moving Higher
at The Street - Wed Sep 10, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
SKBI: 3.79 (-0.11), REPH: 10.71 (-0.78)

Skystar Bio-Pharmaceutical (SKBI) Upgraded From Hold to Buy
at The Street - Tue Sep 09, 8:21AM CDT
Skystar Bio-Pharmaceutical (SKBI) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
SKBI: 3.79 (-0.11)

Skystar to Launch Probiotic Supplement for Dairy Cows by End of Fiscal 2014
Marketwire - Tue Aug 26, 8:04AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced preparations to launch a new probiotic product for dairy cows by the end of fiscal 2014. The dairy cow probiotic is developed for the milk production industry in China and is designed to introduce Bacillus Subtilis (B. subtilis), also known as "Hay Bacillus," into the digestive tract of milk producing cows. Hay Bacillus has been proven to aid in the digestion and breakdown of hay in the animals' rumen canal.
SKBI: 3.79 (-0.11)

Skystar Bio-Pharmaceutical Reports Second Quarter Fiscal Year 2014 Financial Results
Marketwire - Thu Aug 14, 5:59PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company" , a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today reported unaudited second quarter fiscal year 2014 earnings, for the period ended June 30, 2014.
SKBI: 3.79 (-0.11)

Skystar Bio-Pharmaceutical to File Financial Results for Second Quarter of Fiscal 2014 on Thursday, August 14
Marketwire - Thu Aug 14, 5:31PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company" , a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its financial results for the second quarter of fiscal 2014 on Thursday, August 14, 2014 by close of the business day.
SKBI: 3.79 (-0.11)

Skystar Bio-Pharmaceutical Announces $5 Million Registered Direct Offering
Marketwire - Wed Jul 16, 7:59AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today announces that it has entered into a definitive agreement with a dedicated healthcare institutional investor to purchase an aggregate of $5,000,000 of registered securities of the Company in a registered direct offering. Pursuant to the terms of the agreement, the investor shall purchase from the Company 790,514 shares of common stock and warrants to purchase up to 197,629 shares of common stock for an aggregate purchase price of $4,000,000 and 1,000 shares of convertible preferred stock and warrants to purchase up to 49,407 shares of common stock for an aggregate purchase price of $1,000,000.
SKBI: 3.79 (-0.11)

Skystar unveils new bovine IgG kits in China for domestic pig farming communities
M2 - Wed Jul 09, 6:32AM CDT
Veterinary company Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) reported on Tuesday the availability of its new product in China, called bovine immunoglobulin G (IgG) kits, targeting China's domestic pig farming communities.
SKBI: 3.79 (-0.11)

Skystar Launches Bovine Immunoglobulin G (IgG) Kits in China
Marketwire - Tue Jul 08, 8:04AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today announced the launch of a new product in China -- bovine immunoglobulin G (IgG) kits targeting China's domestic pig farming communities. This product helps to prevent and treat blue ear disease, respiratory pneumonia, pseudorabies, swine fever and foot and mouth disease which are common diseases affecting pig in the farming industry.
SKBI: 3.79 (-0.11)

23.3% Return Seen to Date on SmarTrend Skystar Bio-Pharmaceutical Call (SKBI)
Comtex SmarTrend(R) - Mon Jul 07, 11:08AM CDT
SmarTrend identified an Uptrend for Skystar Bio-Pharmaceutical (NASDAQ:SKBI) on April 24th, 2014 at $6.32. In approximately 2 months, Skystar Bio-Pharmaceutical has returned 23.26% as of today's recent price of $7.79.
SKBI: 3.79 (-0.11)

12.7% Return Seen to Date on SmarTrend Skystar Bio-Pharmaceutical Call (SKBI)
Comtex SmarTrend(R) - Fri Jun 27, 9:26AM CDT
SmarTrend identified an Uptrend for Skystar Bio-Pharmaceutical (NASDAQ:SKBI) on April 24th, 2014 at $6.32. In approximately 2 months, Skystar Bio-Pharmaceutical has returned 12.66% as of today's recent price of $7.12.
SKBI: 3.79 (-0.11)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 193

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 0

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 125

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 102

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 67

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 48

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 55

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 131

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading

Top 5 Most Recently Viewed Articles

BioMarin's Strong 2024 Performance Fuels 2025 Expectations

Updated Category News Views 392

BioMarin's Empowering Growth Journey Into 2025 BioMarin Pharmaceutical Inc. has marked a significant achievement with its record performance in 2024, setting a strong foundation for the upcoming year. The company demonstrated robust operational execution and is gearing up for a year of potential double-digit revenue growth as it advances its corporate strategy focusing on...

Continue Reading
Berkshire Hills Bancorp Declares Cash Dividend for Shareholders

Updated Category News Views 104

Berkshire Hills Bancorp Announces Quarterly Dividend Berkshire Hills Bancorp, Inc. (NYSE: BHLB) has recently declared a quarterly cash dividend of $0.18 per common share for its shareholders. This decision by the Board of Directors aims to reward shareholders who are on record by a specified date. Details of the Dividend Announcement The approved cash dividend will be...

Continue Reading
Maiden United Transforms Adele's Skyfall into Heavy Metal Epic

Updated Category News Views 167

Maiden United Transforms Iconic Adele Song into Heavy Metal What if Iron Maiden had recorded the legendary James Bond theme song? Maiden United, a notable tribute band dedicated to Iron Maiden, has taken that intriguing concept and turned it into reality. The band has just unveiled their latest EP entitled Agent 666, which features an electrifying heavy metal cover of...

Continue Reading
Cherokee Federal Boosts Growth with MSI, LLC Investment

Updated Category News Views 213

Cherokee Federal Expands Presence Through Strategic Investment Cherokee Federal, a division of Cherokee Nation Businesses (CNB), has recently announced a significant move in the federal contracting realm. They have acquired a majority stake in Management Science and Innovation, LLC, also known as MSI. This strategic investment marks another milestone under their...

Continue Reading
Metallurgical Coal Market Expected Growth Amid Steel Demand Spike

Updated Category News Views 125

Growth of the Metallurgical Coal Market The global metallurgical coal market is poised for significant growth, estimated at USD 95.27 billion from 2024 to 2028. This growth is largely driven by the increasing demand for steel, which is essential for numerous infrastructure projects around the world. As smart city developments surge, the necessity for high-quality steel...

Continue Reading